May 2, 2023 11:31 AM EDTUpdated 01:12 PM

Exelixis gives more details behind Farallon proxy fight

Paul Schloesser

Associate Editor

Oncology biotech Exelixis is defending its business amid a proxy fight with a hedge fund that has criticized the company’s R&D strategy and spending. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Exelixis gives more details behind Farallon proxy fight

Paul Schloesser

Associate Editor

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Pharma's wins and losses in Trump's sprawling executive order on drug prices

In a blow to its obesity pipeline, Pfizer drops oral drug after liver injury case

Exclusive: A small biotech will bring Roche's Angelman drug back to life

Eli Lilly reports first Phase 3 data for oral GLP-1, posting a win in diabetes

What's Pfizer's next move after shelving its oral obesity drug danuglipron?

New York-based partnership sets the standard for expanding clinical trial access for underserved and diverse ...

Ex­elix­is gives more de­tails be­hind Far­al­lon proxy fight

Associate Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Exelixis gives more details behind Farallon proxy fight